ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ImmunoForge Inc. receives U.S. FDA ODD for PF1801
October 29, 2021ImmunoForge (Co-CEOs Sung-Min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801... -
Immunoforge's 'PF1801' Is Designated as Orphan Drug by FDA
January 29, 2021Immunoforge announced that their new drug candidate PF1801 has been designated as the FDA orphan drug for treatment of the Duchenne muscular dystrophy on January 25.
Pharma Sources Insight January 2025
